Calliditas Therapeutics AB (publ)’s (CALT) “Hold” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed their hold rating on shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $40.00 price target on the stock, down from their prior price target of $55.00.

Separately, HC Wainwright reissued a neutral rating and issued a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Calliditas Therapeutics AB (publ) currently has a consensus rating of Hold and an average target price of $34.00.

Read Our Latest Stock Report on CALT

Calliditas Therapeutics AB (publ) Price Performance

Shares of NASDAQ CALT opened at $38.47 on Tuesday. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -20.80 and a beta of 1.50. Calliditas Therapeutics AB has a fifty-two week low of $15.25 and a fifty-two week high of $39.10. The firm’s 50-day simple moving average is $21.61 and its 200 day simple moving average is $21.65. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) last released its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). The company had revenue of $28.43 million during the quarter, compared to analysts’ expectations of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. As a group, research analysts anticipate that Calliditas Therapeutics AB will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new stake in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Featured Articles

Analyst Recommendations for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.